Are peptides legal in Israel?
Sourced guide to the legal status of peptides in Israel, refreshed automatically from live research.
Overall Status: Gray Area
Short answer: Peptides such as BPC-157 and TB-500 are not approved medicines in Israel and have no dedicated peptide-specific statute, so they fall under Israel's general prescription-drug and unapproved-drug framework, which treats unapproved research peptides as unlawful to sell or supply for human use outside a licensed pharmaceutical/prescription channel.
Important: This information is for educational purposes only and does not constitute legal advice. Laws and enforcement policies change. Consult a qualified attorney for specific legal guidance.
Overview
Peptides are in a legal gray zone in Israel: there is no peptide-specific law naming BPC-157, TB-500, or similar research peptides, so their status is inferred from Israel's general medicines framework rather than a dedicated statute. Products that are approved medicines (such as semaglutide-class GLP-1 drugs or recombinant human growth hormone) are prescription-only and regulated as pharmaceuticals, while unapproved 'research chemical' peptides are not licensed for human use anywhere and would not be lawfully sellable as human-use products under a general unapproved-drug standard. Because a live, exhaustive search of Israeli government sources (Ministry of Health guidance, the Pharmacists' Ordinance, customs personal-import rules) could not be completed in this session, the Israel-specific mechanics below are marked unsourced rather than asserted as fact.
Key Points
- No Israel-specific statute or regulation naming BPC-157, TB-500, or similar 'research peptides' was located, meaning their status in Israel is inferred from the general medicines/prescription-drug framework rather than a dedicated peptide law. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)
- BPC-157 has not been approved for human clinical use by the FDA or by any other global health authority, a status that underlies why it is not marketed as an approved medicine in most countries, including Israel. [1]
- Approved medicines in the semaglutide/GLP-1 class and human growth hormone products are prescription-only pharmaceuticals in Israel, requiring a physician's prescription dispensed through a licensed pharmacy rather than over-the-counter sale. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)
- Personal importation of prescription medicines into Israel for individual use typically requires a valid prescription and is limited to a personal-use quantity, but the exact quantity limits and whether unapproved research peptides like BPC-157 or TB-500 are permitted under this pathway could not be confirmed with a retrievable Israeli government source in this session. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)
- No recent (2023-2026) Israel-specific bill, regulatory amendment, or public enforcement action targeting peptide research chemicals could be located and verified in this session. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)
- Israel's Ministry of Health functions as the primary national regulator overseeing drug registration, prescription-medicine status, and pharmacy practice, making it the body whose general (not peptide-specific) rules would govern any peptide sold or prescribed in Israel. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)
Peptide-by-peptide status in Israel
| BPC-157 | BPC-157 is not an approved medicine anywhere, including Israel, and is not listed in the FDA's or any comparable regulator's approved-drug database, meaning it functions as an unapproved research chemical rather than a legal prescription product in Israel. [1] |
|---|
| TB-500 (Thymosin Beta-4) | TB-500 has the same unapproved research-chemical status as BPC-157 internationally, and no Israel-specific source confirming a distinct legal status for it in Israel could be verified in this session. |
|---|
| Semaglutide / tirzepatide (GLP-1 class) | Approved semaglutide and tirzepatide products for diabetes or weight management are prescription-only pharmaceuticals in Israel when marketed as registered branded medicines, but this could not be confirmed against a specific Israeli Ministry of Health source in this session. |
|---|
| Human Growth Hormone (HGH/somatropin) | Somatropin/HGH is treated as a prescription-only pharmaceutical requiring physician oversight in most jurisdictions, and this pattern is presumed to apply in Israel as well, though a direct Israeli regulatory citation could not be retrieved in this session. |
|---|
Last researched: 2026-09-10
Frequently asked questions
No verified Israeli source confirms an over-the-counter legal sale channel for BPC-157 or similar unapproved research peptides in Israel; internationally, BPC-157 is not approved for human clinical use by any regulator, which typically precludes lawful non-prescription sale for human consumption.
[1]
This could not be confirmed against Israeli customs or Ministry of Health import rules in this research session; travelers should check current Israeli Ministry of Health personal-import guidance directly before attempting to bring unapproved peptides into the country.
Whether Israeli telehealth prescribing rules specifically permit remote prescription of GLP-1 medicines or peptides such as BPC-157 could not be verified with a retrievable Israeli regulatory source in this session.
No specific Israeli enforcement action, penalty schedule, or case example concerning peptide research chemicals could be located and verified in this research session.
No: BPC-157 is not approved for human clinical use by the FDA or by any other global health authority, and no Israel-specific approval was found, so it remains an unapproved research chemical rather than a registered medicine in Israel.
[1]